Krakow, Poland – 24 September – Selvita will participate as a panelist at the “Charting Poland’s Future Event: Spotlight on Growth & Innovation”, which is taking place on September 25, 2018, in London, in Bloomberg’s new European Headquarters.
Selvita CEO Pawel Przewiezlikowski will participate in a panel discussion “The View from the C-Suite”, focusing on the role of CEOs, from the largest and fastest growing companies, in Poland’s transformation, and their journey towards that goal. They will discuss existing limitations and future opportunities, and what their strategic focus should be moving forward. During the panel, Pawel Przewiezlikowski will present his perspective on growing drug discovery companies under the conditions of the current market.
Other experts on the panel:
Anna Rulkiewicz, CEO of LUX MED
Maciej Dziergwa, CEO of STX Next
Martin Balawajder, CFO of 11 Bit Studios
Michał Krupiński, CEO of Bank Pekao
Panel: The View from the C-Suite
Date: Tuesday 25th September 2018
Time: 8:30am – 11:00am
Location: 3 Queen Victoria St, London, UK
To find out more about the Bloomberg event visit:
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
+48 660 797 362